Marlborough-based Sunovion Pharmaceuticals announced a drug used to treat schizophrenia and bipolar depression was well-tolerated in patients and was associated with improved depressive symptoms in a secondary analysis.
The drug Latuda, when taken once a day for six months following a six-week placebo controlled treatment period, was well tolerated with small changes in metabolic parameters, Sunovion’s study found. A secondary analysis found the drug to be associated with improvement in depressive symptoms, based on observed case data over time and assessed using a depression rating scale.
The results from the six-month, open-label extension study were published the journal Depression and Anxiety, the company announced Monday. The study was designed to evaluate the drug’s long-term safety potential in patients with bipolar depression and tested Latuda both alone and as an adjunctive therapy, according to the company.
Â
CORRECTION: A previous version of this article incorrectly stated that Latuda was well tolerated with small changes in weight and metabolism. This has been changed to say “metabolic parameters.”Â
Â
Â
Â
Â
